Evidence map›Paper›PMID 41708844›Full record

ArticleAAPS PharmSciTech2026

The PAH-AM-PEG-ApoE@siRNA Nanocarrier Delivery System for Polo-like Kinase 1 Inhibition Suppresses Glioma Progression.

Feng Su, Shengnan Lu, Junli Zhang, Yu Zhang, Yaoyao Zhang, Ling Cheng, Jing Li, Ying Li, Guangwei He, Lifang Yin

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Feng SuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China.ORCID http://orcid.org/0009-0002-5641-7115
Shengnan LuHefei Industrial Pharmaceutical Institute Co., Ltd, Anhui Provincial Key Laboratory of Drug Innovation and Advanced Pharmaceuticals, Hefei, 230088, China.ORCID http://orcid.org/0009-0003-3187-5010
Junli ZhangSchool of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.ORCID http://orcid.org/0009-0001-5352-8998
Yu ZhangSchool of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.ORCID http://orcid.org/0009-0006-3179-1249
Yaoyao ZhangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China.ORCID http://orcid.org/0009-0004-5604-3197
Ling ChengDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China.ORCID http://orcid.org/0009-0001-9402-338X
Jing LiDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China.ORCID http://orcid.org/0009-0001-6057-6314
Ying LiHefei Industrial Pharmaceutical Institute Co., Ltd, Anhui Provincial Key Laboratory of Drug Innovation and Advanced Pharmaceuticals, Hefei, 230088, China.ORCID http://orcid.org/0009-0004-7256-1138
Guangwei HeSchool of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China. heguangwei@ahipi.com.ORCID http://orcid.org/0009-0005-4667-8399
Lifang YinDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, 211198, China. lifangyin@cpu.edu.cn.ORCID http://orcid.org/0000-0002-2825-3136

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The poor efficacy of chemotherapy for glioma is mainly due to the difficulty of drug penetration through the blood-brain barrier (BBB), as well as the difficulty of drug concentration in the tumor tissue to reach the effective therapeutic level. The emerging tumor-targeted delivery technology can facilitate the precise enrichment of drugs in the tumor site. Apolipoprotein E (ApoE(159-167)

Indexed as

Cell Cycle ProteinsDrug CarriersGliomaNanoparticlesPolyethylene GlycolsProtein Serine-Threonine KinasesProto-Oncogene ProteinsRNA, Small InterferingAnimalsBlood-Brain BarrierBrain NeoplasmsCell Line, TumorDrug Delivery SystemsHumansMaleMiceCell Cycle ProteinsDrug CarriersNanoparticle Drug Delivery SystemPolo-Like Kinase 1Polyethylene GlycolsProtein Serine-Threonine KinasesProto-Oncogene ProteinsRNA, Small Interferingbrian-targetedgliomaPAH derivativesself-assembly methodsiRNA nanocarrier delivery system

Identifiers

PMID41708844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.